Azeez Amida unveils “Enter, Perform, Exit (EPE Principle): Understanding the Opportunity Cycle” to thunderous applause in Lagos

Already a bestseller in its rights, the book topped the list of hottest publications on Amazon and continues to receive rave reviews and reviews from Madrid, New York, Addis Ababa, Kigali, Milan, Johannesburg and many other cities around the world.

According to the author, the book offers career professionals, executives, and leaders of all levels the right blend of old world learnings and new age solutions to generate extraordinary growth.





















Guests at the event represented young professionals, members of the diplomatic corps, small business owners, global leaders, successful business owners and senior executives, including the cultural attaché to the French Ambassador to the Nigeria, Emmanuelle Harang; CEO of Chapel Hill Denham, Bolaji Balogun; Life and Behavior Change Catalyst, Dr. Lanre Olusola; and director of the Alliance française, Marc Brebant.


























Anchored by media personality and lifestyle influencer Anto Lecky, the event also included a book-reading session by radio personality and voice-over artist Mazino Appeal Ofoh and Mazars Consulting CEO Adeyemi Sanni ( PhD).

CEO of Chapel Hill Denham, Bolaji Balogun, who gave the keynote, praised Azeez Amida for writing a book that sheds light on deep insights and provides guidance on tools and techniques that enable success, self-discovery, vision and purpose .



























“I am happy that Azeez Amida was able to put everything he has learned over the years into a book. It will be beneficial for those who are still finding their way. There is a lot to learn from the book. Anything is possible. To realize your potential, you must be hardworking, excellent and resilient,” he said.

Azeez Amida, who has a proven track record of high performance and international impact in the corporate world and in the leadership space, said he was delighted with the deep appreciation and acceptance that the book had aroused since its release.

He revealed that the book is his way of sharing his real-world experiences and valuable tips for productivity and excellence with people who aim to perform at their best. He said the book contains the essential ingredients for success and resilience in different spheres of life.


“When I started writing this book, I didn’t expect it to turn out like this. The hardest part of writing it was the first chapter,” said Amida during a conversation between an author and Peak Performance strategist Dr. Abiola Salami.

















“I thought it was going to be easy. I already set myself a goal of how long I wanted to write the book. When I spoke with one of the publishing houses, they said I wouldn’t sell any more. of a few hundred copies, but the recoption and the feedback since it went on sale has been incredible and mind-blowing.”

Amida revealed that in just one weekend before the official book presentation and launch, they sold over 1,500 copies of EPE Principle. “I’ve been really amazed by the response so far, and it challenges me to do more and be more,” he added.

The event also featured a fireside chat about exploiting growth opportunities and knowing when to exit. The insightful panel was moderated by GLG Communications Managing Partner Omawumi Ogbe, in conversation with Inkblot Productions Co-Founder Zulumoke Oyibo; CEO of Liquid Telecoms, Wole Abu; and Managing Partner of Partners in People Africa, Michael Thomas.

Enter, Execute, Exit (EPE Principle): Understanding the Opportunity Cycle is currently available with nationwide delivery to Roving Heights; and in paperback, hardback, ebook and audiobook formats at Amazon, Barnes & Noble and wherever books are sold online worldwide.

According to Dr. Lanre Olusola, “The book is a must-have for anyone looking to break out of the endless cycle of average and live a life where they maximize their highest potential.”

To learn more about Amida and his book, visit www.azeezamida.com and follow him on social media, @azeezamida.

Comments are closed.